PROGNOSIS OF HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER (HNPCC) AND THE ROLE OF JAPANESE CRITERIA FOR HNPCC

Citation
S. Fujita et al., PROGNOSIS OF HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER (HNPCC) AND THE ROLE OF JAPANESE CRITERIA FOR HNPCC, Japanese Journal of Clinical Oncology, 26(5), 1996, pp. 351-355
Citations number
16
Categorie Soggetti
Oncology
ISSN journal
03682811
Volume
26
Issue
5
Year of publication
1996
Pages
351 - 355
Database
ISI
SICI code
0368-2811(1996)26:5<351:POHNC(>2.0.ZU;2-L
Abstract
In 1991, the Japan Research Society for Cancer of the Colon and Rectum proposed clinical criteria (Japanese criteria) for hereditary nonpoly posis colorectal cancer (HNPCC). According to the Japanese and Amsterd am criteria, three groups of patients are defined: 1) those diagnosed as having HNPCC using the Amsterdam criteria (Amsterdam HNPCC); 2) tho se classified as Japanese criteria category A (putative HNPCC-A) and 3 ) those classified as Japanese criteria category B (putative HNPCC-B). In order to evaluate the prognosis of HNPCC and the role of the Japan ese criteria, the clinicopathological characteristics, recurrence and survival rates of Amsterdam HNPCC (n 14) and putative HNPCC-A (n 31) a nd B (n 100) patients were studied, and compared with those of patient s with sporadic colorectal cancer (controls, n 1604). The Amsterdam cl inicopathological characteristics and those of putative HNPCC were the same as those reported previously. Neither local nor distant recurren ces were observed in the Amsterdam HNPCC and putative HNPCC-A during a median follow-up period of 137 months. The 5-year survival rates of t he Amsterdam HNPCC, putative HNPCC-A, B, and control patients were 92. 3%, 81.2%, 66.5% and 60.0%, respectively, and those of the former two groups were significantly better than those of the others (P < 0.05). These results show that the prognosis of HNPCC is better than that of sporadic colorectal cancer, and that the Japanese criteria, especially for category A, can be used to select putative HNPCC patients from am ong those with sporadic colorectal cancers.